Skip to main content

Hepal-6 Derived RNA Electroporated Murine Spleen B Cells Induced Antitumor Effects In Vivo

Buy Article:

$45.00 plus tax (Refund Policy)

RNA electroporated CD40 ligand-activated B cells can induce cytotoxic T-lymphocyte response in vitro. In order to evaluate the effects in vivo, we applied murine spleen B cell vaccine in a mouse model of liver cancer. C57BL/6 mouse spleen B cells were activated by anti-mouse CD40 antibody, recombinant interleukin-4, and cyclosporin A, and then electroporated with total RNA from Hepal-6 cells (Hepal-6 RNA-CD40mAb-B cells). This vaccine was injected into C57BL/6 mice that were subcutaneously inoculated with Hepal-6 cells. Hepal-6 RNA-CD40mAb-B cells could induce tumor-specific cytotoxic T cells and IFN-γ secretion in the immunized mice. In vivo study showed this vaccine could well inhibit tumor progression, improve overall survival, and provide continuous immunoprotection against Hepal-6 cell-induced tumor. Tumor cell-derived total RNA electroporated B cells vaccine is a type of effective immunotherapy and provides potential implication for clinical treatment.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: B cell; C57BL/6 mouse; CD40; Hepatocellular carcinoma; Immunotherapy

Document Type: Research Article

Publication date: 01 January 2009

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more